(Q29616694)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

30 April 2017

author name string

Holohan C

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

30 April 2017

Van Schaeybroeck S

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

30 April 2017

Longley DB

3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

30 April 2017

Johnston PG

4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

October 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

30 April 2017

published in

Nature Reviews Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

30 April 2017

volume

13

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

30 April 2017

issue

10

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

30 April 2017

page(s)

714-26

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

Molecular mechanisms of drug resistance

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Intratumor heterogeneity: evolution through space and time

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Multidrug resistance in cancer: role of ATP-dependent transporters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Mammalian ABC transporters in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Strategies for reversing drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Death receptors in chemotherapy and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Intrinsic tumour suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Identifying DNA methylation biomarkers of cancer drug response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Cancer stem cell definitions and terminology: the devil is in the details.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

A multidrug resistance transporter from human MCF-7 breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Expression of multidrug resistance genes in normal and cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Role of uridine phosphorylase in the anabolism of 5-fluorouracil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

An epigenetic mechanism for capecitabine resistance in mesothelioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

5-Fluorouracil: mechanisms of action and clinical strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

ALK-positive anaplastic large cell lymphoma with TPM3-ALK translocation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Oncogenic mutations of ALK kinase in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Overriding imatinib resistance with a novel ABL kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Noncovalent wild-type-sparing inhibitors of EGFR T790M

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

The concept of synthetic lethality in the context of anticancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Resistance to therapy caused by intragenic deletion in BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Chromosomal instability determines taxane response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

31 March 2020

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Diagnosing and exploiting cancer's addiction to blocks in apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

A role for mitochondrial Bak in apoptotic response to anticancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

31 March 2020

The BCL-2 family reunion

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Towards novel paradigms for cancer therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

c-FLIP: a key regulator of colorectal cancer cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

The inhibitors of apoptosis (IAPs) as cancer targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Smac mimetics as new cancer therapeutics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Deconvoluting the context-dependent role for autophagy in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Stromal fibroblasts in cancer initiation and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Immune microenvironments in solid tumors: new targets for therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

The role of tumour-stromal interactions in modifying drug response: challenges and opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

New perspectives in cell adhesion: RGD and integrins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Integrins as novel drug targets for overcoming innate drug resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Integrins: regulators of tissue function and cancer progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

DNA damage-mediated induction of a chemoresistant niche

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

ABC transporters, drug resistance, and cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Colon cancer stem cells: promise of targeted therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

The cancer stem cell: premises, promises and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

ROS1 rearrangements define a unique molecular class of lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC3599

A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance

31 March 2020

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

Tissue elasticity properties as biomarkers for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

The role of DNA mismatch repair in drug resistance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

'Role of bone marrow stromal cells in the growth of human multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060863

12 December 2020

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24060863

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

274328

Dimensions Publication ID

1026519625

0 references

OpenCitations bibliographic resource ID

274328

1 reference